{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:53:38Z","timestamp":1789084418751,"version":"build-2803163510"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute kidney injury (AKI) is a common complication of cancer that occurs in up to 50% of neoplastic patients during the natural history of their disease; furthermore, it has a huge impact on key outcomes such as overall prognosis, length of hospitalization and costs. AKI in cancer patients has different causes, either patient-, tumour- or treatment-related. Patient-related risk factors for AKI are the same as in the general population, whereas tumour-related risk factors are represented by compression, obstruction, direct kidney infiltration from the tumour as well by precipitation, aggregation, crystallization or misfolding of paraprotein (as in the case of multiple myeloma). Finally, treatment-related risk factors are the most common observed in clinical practice and may present also with the feature of tumour lysis syndrome or thrombotic microangiopathies. In the absence of validated biomarkers, a multidisciplinary clinical approach that incorporates adequate assessment, use of appropriate preventive measures and early intervention is essential to reduce the incidence of this life-threatening condition in cancer patients.<\/jats:p>","DOI":"10.1093\/ckj\/sfaa127","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T15:11:25Z","timestamp":1594307485000},"page":"70-83","source":"Crossref","is-referenced-by-count":45,"title":["Preventive strategies for acute kidney injury in cancer patients"],"prefix":"10.1093","volume":"14","author":[{"given":"Laura","family":"Cosmai","sequence":"first","affiliation":[{"name":"Onco-Nephrology Outpatient Clinic, Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Fatebenefratelli Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, University of Bari \u2018A. Moro\u2019, Bari, Italy"},{"name":"Division of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Foramitti","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[{"name":"Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Mollica","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari"},{"name":"Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2011-2160","authenticated-orcid":false,"given":"Maurizio","family":"Gallieni","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biomedical Sciences \u2018Luigi Sacco\u2019, University of Milano, Milan, Italy"},{"name":"Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Capasso","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018L. Vanvitelli\u2019, Naples, Italy"},{"name":"Biogem Research Institute, Ariano Irpino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,28]]},"reference":[{"key":"2021020321153384900_sfaa127-B1"},{"key":"2021020321153384900_sfaa127-B2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"key":"2021020321153384900_sfaa127-B3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2021020321153384900_sfaa127-B4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.23876\/j.krcp.19.042","article-title":"Acute kidney injury in the patient with cancer","volume":"38","author":"Rosner","year":"2019","journal-title":"Kidney Res Clin Pract"},{"key":"2021020321153384900_sfaa127-B5","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ndt\/gfn009","article-title":"ANZICS Database Management Committee. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients","volume":"23","author":"Bagshaw","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2021020321153384900_sfaa127-B6"},{"key":"2021020321153384900_sfaa127-B7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2215\/CJN.03530412","article-title":"Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center","volume":"8","author":"Salahudeen","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","article-title":"Acute kidney injury","volume":"394","author":"Ronco","year":"2019","journal-title":"Lancet"},{"key":"2021020321153384900_sfaa127-B9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer. A population-based cohort study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2021020321153384900_sfaa127-B10","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1038\/s41598-019-39735-9","article-title":"Acute kidney injury in cancer patients: a nationwide survey in China","volume":"9","author":"Jin","year":"2019","journal-title":"Sci Rep"},{"key":"2021020321153384900_sfaa127-B11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.kint.2019.04.043","article-title":"Summary of the international conference on onco-nephrology: an emerging field in medicine","volume":"96","author":"Capasso","year":"2019","journal-title":"Kidney Int"},{"key":"2021020321153384900_sfaa127-B12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7861\/clinmedicine.13-3-233","article-title":"Identification of risk factors associated with acute kidney injury in patients admitted to acute medial units","volume":"13","author":"Finlay","year":"2013","journal-title":"Clin Med"},{"key":"2021020321153384900_sfaa127-B13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4111\/icu.2018.59.6.376","article-title":"Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction","volume":"59","author":"Yoon","year":"2018","journal-title":"Investig Clin Urol"},{"key":"2021020321153384900_sfaa127-B14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clon.2010.07.004","article-title":"Percutaneous urinary drainage and ureteric stenting in malignant disease","volume":"22","author":"Allen","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2021020321153384900_sfaa127-B15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MCC.0000000000000253","article-title":"Acute kidney injury in hematological patients","volume":"21","author":"Canet","year":"2015","journal-title":"Curr Opin Crit Care"},{"key":"2021020321153384900_sfaa127-B16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1258\/ar.2011.110523","article-title":"Prevalence and patterns of renal involvement in imaging of malignant lymphoproliferative diseases","volume":"53","author":"Bach","year":"2012","journal-title":"Acta Radiol"},{"key":"2021020321153384900_sfaa127-B17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5301\/jo-n.5000030","article-title":"AKI in multiple myeloma: paraproteins, metabolic disturbances, and drug toxicity","volume":"1","author":"Shah","year":"2017","journal-title":"J Onco-Nephrol"},{"key":"2021020321153384900_sfaa127-B18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.ajkd.2019.04.029","article-title":"Dysproteinemia and the kidney: core curriculum 2019","volume":"74","author":"Hogan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2021020321153384900_sfaa127-B19","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2215\/CJN.01640216","article-title":"Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy","volume":"11","author":"Finkel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B20","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1172\/JCI46490","article-title":"Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model","volume":"122","author":"Ying","year":"2012","journal-title":"J Clin Invest"},{"key":"2021020321153384900_sfaa127-B21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ckj\/sfy065","article-title":"Treatment of multiple myeloma with renal involvement: the nephrologist's view","volume":"11","author":"Fav\u00e0","year":"2018","journal-title":"Clin Kidney J"},{"key":"2021020321153384900_sfaa127-B22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ki.1985.8","article-title":"Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat","volume":"27","author":"Holland","year":"1985","journal-title":"Kidney Int"},{"key":"2021020321153384900_sfaa127-B23","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2215\/CJN.05100418","article-title":"Extracorporeal removal of light chains: new data and continued controversies","volume":"13","author":"Finkel","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s11523-018-0601-2","article-title":"Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis evaluating cytoreductive nephrectomy in the era of targeted therapy","volume":"13","author":"Massari","year":"2018","journal-title":"Target Oncol"},{"key":"2021020321153384900_sfaa127-B25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"2021020321153384900_sfaa127-B26","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00345-012-1001-3","article-title":"Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis","volume":"31","author":"Tsao","year":"2013","journal-title":"World J Urol"},{"key":"2021020321153384900_sfaa127-B27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.11941116","article-title":"Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis","volume":"12","author":"Patel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B28","doi-asserted-by":"crossref","first-page":"486.e17\u2013486","DOI":"10.1016\/j.urolonc.2016.05.034","article-title":"Disease progression and kidney function after partial vs radical nephrectomy for T1 renal cancer","volume":"34","author":"Forbes","year":"2016","journal-title":"Urol Oncol"},{"key":"2021020321153384900_sfaa127-B29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2019.04.003","article-title":"Value of partial nephrectomy for renal cortical tumors of cT2 or greater stage: a risk-benefit analysis of renal function preservation versus increased postoperative morbidity","volume":"3","author":"Vilaseca","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"2021020321153384900_sfaa127-B30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.urolonc.2018.11.007","article-title":"Assessment of volume preservation performed before or after partial nephrectomy accurately predicts postoperative renal function: results from a prospective multicenter study","volume":"37","author":"Klingler","year":"2019","journal-title":"Urol Oncol"},{"key":"2021020321153384900_sfaa127-B31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.eururo.2016.03.023","article-title":"End-stage renal disease after renal surgery in patients with normal preoperative kidney function: balancing surgical strategy and individual disorders at baseline","volume":"70","author":"Capitanio","year":"2016","journal-title":"Eur Urol"},{"key":"2021020321153384900_sfaa127-B32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.euf.2017.02.012","article-title":"Renal preservation and partial nephrectomy: patient and surgical factors","volume":"2","author":"Marconi","year":"2016","journal-title":"Eur Urol Focus"},{"key":"2021020321153384900_sfaa127-B33","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1681\/ASN.2015121335","article-title":"The Nephrologist\u2019s tumor: basic biology and management of renal cell carcinoma","volume":"27","author":"Hu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: a review","volume":"334","author":"Yao","year":"2007","journal-title":"Am J Med Sci"},{"key":"2021020321153384900_sfaa127-B35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","article-title":"Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity","volume":"26","author":"Volarevic","year":"2019","journal-title":"J Biomed Sci"},{"key":"2021020321153384900_sfaa127-B36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1345\/aph.1Q333","article-title":"The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy","volume":"46","author":"Morgan","year":"2012","journal-title":"Ann Pharmacother"},{"key":"2021020321153384900_sfaa127-B37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systemic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"2021020321153384900_sfaa127-B38","first-page":"1873","article-title":"Hydration with 15 mEq magnesium is effective at reducing the risk for cisplatin-induced nephrotoxicity in patients receiving cisplatin (\u226550 mg\/m2) combination chemotherapy","volume":"36","author":"Yamamoto","year":"2016","journal-title":"Anticancer Res"},{"key":"2021020321153384900_sfaa127-B39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00520-016-3426-5","article-title":"Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity","volume":"25","author":"Saito","year":"2017","journal-title":"Support Care Cancer"},{"key":"2021020321153384900_sfaa127-B40","first-page":"168","article-title":"Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity","volume":"33","author":"Dana","year":"1996","journal-title":"Indian J Cancer"},{"key":"2021020321153384900_sfaa127-B41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13318-017-0436-8","article-title":"Pharmacokinetic-pharmacodynamic analysis of cisplatin with hydration and mannitol diuresis: the contribution of urine cisplatin concentration to nephrotoxicity","volume":"43","author":"Fukushima","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2021020321153384900_sfaa127-B42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1006490226104","article-title":"A randomized trial comparing the nephrotoxicity of cisplatin\/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors","volume":"18","author":"Hartmann","year":"2000","journal-title":"Invest New Drugs"},{"key":"2021020321153384900_sfaa127-B43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s002800050026","article-title":"In vitro antioxidant properties of Amifostine (WR-2721, Ethyol)","volume":"45","author":"Marzatico","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021020321153384900_sfaa127-B44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.15171\/jnp.2017.41","article-title":"Phytotherapy of nephrotoxicity-induced by cancer drugs: an updated review","volume":"6","author":"Heidari-Soreshjani","year":"2017","journal-title":"J Nephropathol"},{"key":"2021020321153384900_sfaa127-B45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Wideman","year":"2006","journal-title":"Oncologist"},{"key":"2021020321153384900_sfaa127-B46","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin and thymidine for high-dose-methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Wideman","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021020321153384900_sfaa127-B47","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicity of high-dose methotrexate","volume":"21","author":"Scott","year":"2016","journal-title":"Oncologist"},{"key":"2021020321153384900_sfaa127-B48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate-induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"key":"2021020321153384900_sfaa127-B49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/sdi.12220","article-title":"What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: high-flux hemodialysis or carboxypeptidase G2?","volume":"27","author":"Kumar","year":"2014","journal-title":"Semin Dial"},{"key":"2021020321153384900_sfaa127-B50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2021020321153384900_sfaa127-B51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/ckj\/sfy035","article-title":"Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study","volume":"12","author":"Menne","year":"2019","journal-title":"Clin Kidney J"},{"key":"2021020321153384900_sfaa127-B52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"2021020321153384900_sfaa127-B53","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40620-019-00691-2","article-title":"The renal adverse effects of cancer immunotherapy","volume":"33","author":"Steinel","year":"2020","journal-title":"J Nephrol"},{"key":"2021020321153384900_sfaa127-B55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.ajkd.2017.11.021","article-title":"Management of acute kidney injury: core curriculum 2018","volume":"72","author":"Moore","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2021020321153384900_sfaa127-B56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"2021020321153384900_sfaa127-B58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"Di Salvatore","year":"2011","journal-title":"Cell Prolif"},{"key":"2021020321153384900_sfaa127-B59","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"2021020321153384900_sfaa127-B60","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","article-title":"Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl disphosphate (FPP) synthase in the kidney: implications for renal safety","volume":"22","author":"Luhe","year":"2008","journal-title":"Toxicol In Vitro"},{"key":"2021020321153384900_sfaa127-B61","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Onchol"},{"key":"2021020321153384900_sfaa127-B62","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1523-1755.2005.00078.x","article-title":"Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors","volume":"67","author":"Hingorani","year":"2005","journal-title":"Kidney Int"},{"key":"2021020321153384900_sfaa127-B63","first-page":"351","article-title":"Acute kidney injury in patients with cancer","volume":"32","author":"Perazella","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"2021020321153384900_sfaa127-B64","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/bmt.2011.46","article-title":"Acute kidney injury following HCT: incidence, risk factors and outcome","volume":"46","author":"Lopes","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2021020321153384900_sfaa127-B65","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.bmt.1705599","article-title":"Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival","volume":"39","author":"Kersting","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021020321153384900_sfaa127-B66","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.ajkd.2004.11.013","article-title":"Comparison of ARF after myeloablative and non-myeloablative hematopoietic cell transplantation","volume":"45","author":"Parikh","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2021020321153384900_sfaa127-B67","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/cc4903","article-title":"Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion","volume":"10","author":"Ricci","year":"2006","journal-title":"Crit Care"},{"key":"2021020321153384900_sfaa127-B68","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/OTT.S103864","article-title":"Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase","volume":"10","author":"Alakel","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2021020321153384900_sfaa127-B69","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021020321153384900_sfaa127-B70","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3324\/haematol.13290","article-title":"Consensus conference on the management of tumor lysis syndrome","volume":"93","author":"Tosi","year":"2008","journal-title":"Haematologica"},{"key":"2021020321153384900_sfaa127-B71"},{"key":"2021020321153384900_sfaa127-B72","first-page":"525","article-title":"Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis","volume":"44","author":"Bellos","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"2021020321153384900_sfaa127-B73","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03150312","article-title":"Onco-nephrology: tumor lysis syndrome","volume":"7","author":"Wilson","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B74","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone. Results of a multicenter phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Onchol"},{"key":"2021020321153384900_sfaa127-B75","first-page":"435","article-title":"Clinical interventions to prevent tumour lysis syndrome in hematologic malignancy: a multisite retrospective chart review","volume":"72","author":"McKenna","year":"2019","journal-title":"Can J Hosp Pharm"},{"key":"2021020321153384900_sfaa127-B76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/cc4907","article-title":"Clinical review: specific aspects of acute renal failure in cancer patient","volume":"10","author":"Darmon","year":"2006","journal-title":"Crit Care"},{"key":"2021020321153384900_sfaa127-B77","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000046589","article-title":"Thrombotic microangiopathy in the cancer patient","volume":"106","author":"Kwaan","year":"2001","journal-title":"Acta Haematol"},{"key":"2021020321153384900_sfaa127-B78","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Trombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B79","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","article-title":"Thombotic microangiopathy with targeted agents","volume":"17","author":"Blake-Haskins","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021020321153384900_sfaa127-B80","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2021020321153384900_sfaa127-B81","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000484970","article-title":"Acute kidney injury in cancer patients","volume":"193","author":"Gallieni","year":"2018","journal-title":"Contrib Nephrol"},{"key":"2021020321153384900_sfaa127-B82","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/MCC.0000000000000657","article-title":"Acute kidney injury in hematopoietic stem cell transplantation","volume":"25","author":"Wanchoo","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"2021020321153384900_sfaa127-B83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.ackd.2013.08.003","article-title":"Glomerular diseases associated with cancer, chemotherapy, and hematopoietic stem cell transplantation","volume":"21","author":"Jhaveri","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2021020321153384900_sfaa127-B84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2215\/CJN.08580719","article-title":"Acute kidney injury and CKD associated with hematopoietic stem cell transplantation","volume":"15","author":"Renaghan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020321153384900_sfaa127-B85","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1148\/radiol.2019192094","article-title":"Use of intravenous iodinated contrast media in patients with kidney disease: consensus, statements from the American College of Radiologists and the National Kidney Foundation","volume":"294","author":"Davenport","year":"2020","journal-title":"Radiology"},{"key":"2021020321153384900_sfaa127-B86","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1535370217745302","article-title":"Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy","volume":"243","author":"George","year":"2018","journal-title":"Exp Biol Med (Maywood)"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/1\/70\/36184797\/sfaa127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/1\/70\/36184797\/sfaa127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T05:04:31Z","timestamp":1612760671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/1\/70\/6008982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,28]]},"published-print":{"date-parts":[[2021,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa127","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,11,28]]}}}